Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia
A Sequential, Two-Part Study to Evaluate the Clinical Benefit, Safety, Pharmacokinetics, and Pharmacodynamics of AT-007 in Pediatric Patients With Classic Galactosemia (CG)
Sponsor: Applied Therapeutics, Inc.
A PHASE2/PHASE3 clinical study on Classic Galactosemia, this trial is completed. The trial is conducted by Applied Therapeutics, Inc. and has accumulated 7 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE2/PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2024 — Nov 2025 [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Mar 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2_PHASE3
▶ Show 2 earlier versions
-
Mar 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2021 — Mar 2022 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Applied Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .